Prostavasin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Prostavasin is a prostaglandin E1 analogue. It is used in the treatment of stage III and IV peripheral arterial occlusive disease (I73.9), the main mechanism of which is vasodilation. However, prostavasin also acts by inhibiting platelet aggregation by activating the specific prostaglandin receptors of the platelets.

Dosage and method of useThis section has been translated automatically.

2x 40 ug in 250 ml NaCl over 2 hours i.v.

An intra-arterial administration is possible. Dosage: 1 x 10-20 ug in 50 ml NaCl over 60 to 120 minutes.

Cave: renal insufficiency. With a creatinine value of more than 1.5 2 x 20 ug i.v., then 2 x 40 ug i.v. Contraindication for liver disease.

PreparationsThis section has been translated automatically.

alprostadil®

LiteratureThis section has been translated automatically.

  1. HA Neumann (2014) The coagulation system. ABW-Scientific Publisher GmbH Berlin

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer